ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.5500
+0.0400 (+1.59%)
At close: 4:00PM EDT

2.5500 0.00 (0.00%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close2.5100
Open2.5300
Bid2.5100 x 1400
Ask2.6000 x 800
Day's Range2.5200 - 2.6050
52 Week Range1.6000 - 4.7000
Volume80,380
Avg. Volume171,739
Market Cap159.631M
Beta (3Y Monthly)3.64
PE Ratio (TTM)N/A
EPS (TTM)-1.6750
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
Trade prices are not sourced from all markets
  • PR Newswire21 days ago

    Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference

    FREMONT, Calif., May 30, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2019 at 9:00 a.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.

  • Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You
    Simply Wall St.last month

    Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You

    Mike Raab has been the CEO of Ardelyx, Inc. (NASDAQ:ARDX) since 2009. This analysis aims first to contrast CEO...

  • Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
    Zackslast month

    Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates

    Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Ardelyx: 1Q Earnings Snapshot

    The Fremont, California-based company said it had a loss of 42 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • PR Newswirelast month

    Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights

    Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines ...

  • Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
    Zackslast month

    Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

    Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What's in the Cards for Axon Enterprise (AAXN) Earnings?
    Zackslast month

    What's in the Cards for Axon Enterprise (AAXN) Earnings?

    Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive its first-quarter 2019 performance.

  • If You Had Bought Ardelyx (NASDAQ:ARDX) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today
    Simply Wall St.2 months ago

    If You Had Bought Ardelyx (NASDAQ:ARDX) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today

    It is doubtless a positive to see that the Ardelyx, Inc. (NASDAQ:ARDX) share price has gained some 43% in the last three months. Meanwhile over the last three years the stock has dropped hard. Tragically, the share price d...

  • East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?
    American City Business Journals3 months ago

    East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer?

    The Fremont company expects results from two late-stage clinical trials in kidney failure patients later this year. The same drug is expected to face a regulatory decision in September for another condition.

  • PR Newswire3 months ago

    Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors

    Dr. Block is one of the world's preeminent nephrologists and a trailblazer in leading clinical development for drugs focused on enhancing the care and treatment of patients suffering from chronic kidney disease (CKD) and end stage renal disease (ESRD) patients on dialysis. Dr. Block has participated extensively in guiding the development of tenapanor, Ardelyx's lead product candidate in Phase 3 clinical trials for the treatment of hyperphosphatemia in ESRD patients on dialysis.

  • PR Newswire3 months ago

    Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology

    FREMONT, Calif., March 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced the publication in the Journal of the American Society of Nephrology (JASN) of results from the first of two Phase 3 pivotal trials for tenapanor to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. During the treatment period, 164 patients completed treatment in one of three randomized dosing groups (3, 10 and 30 mg titration) of tenapanor twice daily.

  • PR Newswire3 months ago

    Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

    Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused ...

  • An Examination Of Ardelyx, Inc. (NASDAQ:ARDX)
    Simply Wall St.4 months ago

    An Examination Of Ardelyx, Inc. (NASDAQ:ARDX)

    I've been keeping an eye on Ardelyx, Inc. (NASDAQ:ARDX) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe ARDXRead More...

  • PR Newswire4 months ago

    Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

    FREMONT, Calif., Feb. 21, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb. 28, 2019 at the Lotte New York Palace Hotel in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.

  • GlobeNewswire4 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • PR Newswire4 months ago

    Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan

    FREMONT, Calif., Feb. 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX) (Ardelyx) today announced that its collaboration partner in Japan, Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151) (Kyowa Hakko Kirin), has initiated a Phase 2 clinical study in Japan evaluating tenapanor for the treatment of hyperphosphatemia patients on dialysis. The achievement of this development milestone triggers a $5 million payment to Ardelyx.

  • Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount
    Simply Wall St.5 months ago

    Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount

    In this article I am going to calculate the intrinsic value of Ardelyx, Inc. (NASDAQ:ARDX) by taking the expected future cash flows and discounting them to today's value. I will Read More...

  • Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock?
    Insider Monkey6 months ago

    Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock?

    Is Ardelyx Inc (NASDAQ:ARDX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market after […]

  • What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?
    Simply Wall St.7 months ago

    What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?

    The big shareholder groups in Ardelyx Inc (NASDAQ:ARDX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...

  • PR Newswire7 months ago

    Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C

    FREMONT, Calif., Nov. 13, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that  the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut. Ardelyx's NDA submission is supported by a clinical package encompassing more than 3,100 patients and healthy volunteers who have participated in Ardelyx trials and an extensive clinical and preclinical data package supporting the excellent safety profile.

  • Associated Press7 months ago

    Ardelyx: 3Q Earnings Snapshot

    The Fremont, California-based company said it had a loss of 39 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • PR Newswire7 months ago

    Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights

    Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 FREMONT, Calif. , Nov. 7, 2018 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today reported business highlights ...

  • PR Newswire8 months ago

    Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus

    FREMONT, Calif., Oct. 26, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced the presentation of preclinical data suggesting therapeutic synergy of tenapanor in combination with sevelamer, the current standard-of-care phosphate binder treatment for hyperphosphatemia, or elevated serum phosphorus. The data, showing that the combination meaningfully reduced serum phosphorus, were presented today in a poster titled "Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats," at the American Society of Nephrology (ASN) Annual Meeting.

  • PR Newswire8 months ago

    Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting

    FREMONT, Calif., Oct. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this weekend at the American College of Gastroenterology (ACG) 2018 Annual Meeting. The poster (P0338), titled "An Open Label Long-Term Safety Trial (T3MPO-3) of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)," was recognized as a Presidential Poster at this year's meeting, a recognition that fewer than five percent of accepted abstracts receive for high quality, novel, unique and interesting research. Tenapanor, Ardelyx's lead product candidate, is a minimally-systemic small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium transporter NHE3 and reduce sodium uptake from the gut.